FISH Demonstrates Treatment-Related Chromosome Damage in Myeloid but not Plasma Cells in Primary Systemic Amyloidosis

References

• Fonseca R., Ahmann G. J., Jalal S. M., Dewald G. W., Larson D. R., Therneau T. M., Gertz M. A., Kyle R. A., Greipp P. R. Chromosomal abnormalities in systemic amyloidosis. British Journal of Haematology 1998; 103: 704–710
   PubMed Web of Science ®Google Scholar
• Lai J. L., Zandecki M., Mary J. Y., Bernardi F., Izydoczyk V., Flactif M., Morel P., Jouet J. P., Bauters F., Facon T. Improved cytogenetics in multiple myeloma: a study of 151 patients including 117 patients at diagnosis. Blood 1995; 85: 2490–2497
   PubMed Web of Science ®Google Scholar
• Sawyer J. R., Waldron J. A., Jagannath S., Barlogie B. Cytogenetic findings in 200 patients with multiple myeloma. Cancer Genetics and Cytogenetics 1995; 82: 41–49
   PubMed Web of Science ®Google Scholar
• Weh H. J., Fiedler W., Hossfeld D. K. Cytogenetics in multiple myeloma: arc we studying the “right” cells. European Journal of Haematology 1990; 45: 236–237
   PubMed Web of Science ®Google Scholar
• Gould J., Alexanian R., Goodacre A., Pathak S., Hecht B., Barlogie B. Plasma cell karyotype in multiple myeloma. Blood 1988; 71: 453–456
   PubMed Web of Science ®Google Scholar
• Dewald G. W., Kyle R. A., Hicks G. A., Greipp P. R. The clinical significance of cytogenetic studies in 100 patients with multiple myeloma, plasma cell leukemia, or amyloidosis. Blood 1985; 66: 380–390
   PubMed Web of Science ®Google Scholar
• Kyle R. A., Gertz M. A. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Seminars in Hematology 1995; 32: 45–59
   PubMed Web of Science ®Google Scholar
• Zandecki M., Lai J. L., Facon T. Multiple myeloma: almost all patients are cytogenetically abnormal. British Journal of Haematology 1996; 94: 217–227
   PubMed Web of Science ®Google Scholar
• Drach J., Angerler J., Schuster J., Thalhammer R., Jäger U., Geissler K., Lechner K., Ludwig H., Huber H. Clonal chromosomal aberrations in plasma cells from patients with monoclonal gammopathy of undetermined significance (MGUS) (abstract). Proceedings of the Annual Meeting of the American Association of Cancer Research 1995; 36: 144
   Google Scholar
• Drach J., Schuster J., Nowotny H., Angerler J., Rosenthal F., Fiegl M., Rothermundt C., Gsur A., Jager U., Heinz R., Lechner K., Ludwig H., Huber H. Multiple myeloma: high incidence of chromosomal aneuploidy as detected by interphase fluorescence in situ hybridization. Cancer Research 1995; 55: 3854–3859
   PubMed Web of Science ®Google Scholar
• Ahmann G. J., Jalal S. M., Juneau A. L., Christensen E. R., Hanson C. A., Dewald G. W., Greipp P. R. A novel three-color, clone-specific fluorescence in situ hybridization procedure for monoclonal gammopathies. Cancer Genetics and Cytogenetics 1998; 101: 7–11
   PubMed Web of Science ®Google Scholar
• Spurbeck J. L., Carlson R. O., Allen J. E., Dewald G. W. Culturing and robotic harvesting of hone marrow, lymph nodes, peripheral blood, fibroblasts, and solid tumors with in situ techniques. Cancer Genetics and Cytogenetics 1988; 32: 59–66
   PubMed Web of Science ®Google Scholar
• Mitelman F. Recommendations of the International Standing Committee on Human Cytogenetic Nomenclature Memphis. S. Karger, Basel 1994, ISCN 1995: An International System for Human Cytogenetic Nomenclature (1995)Tennessee USA October
   Google Scholar
• Morrison-DeLap S. J., Kuffel D. G., Dewald G. W., Letendre L. Unbalanced 1,7 translocation and therapy-induced hematologic disorder: a possible relationship. American Journal of Hematology 1986; 21: 39–37
   PubMed Web of Science ®Google Scholar
• Weh H. J., Seeger D., Junge I., Hossfeld D. K. Trisomy 8 preceding diagnosis of acute nonlymphocytic leukemia by 2 years in a patient with multiple myeloma without cytological evidence of myelodysplasia. Annals of Hematology 1996; 72: 81–82
   PubMed Web of Science ®Google Scholar
• Cuzick J., Erskine S., Edelman D., Galton D. A. A comparison of the incidence of the myelodysplastic syndrome and acute myeloid leukaemia following melphalan and cyclophosphamide treatment for myelomatosis. A report to the Medical Research Council's working party on leukaemia in adults. British Journal of Cancer 1987; 55: 523–529
   PubMed Web of Science ®Google Scholar
• Rosner F., Grunwald H. W. Simultaneous occurrence of multiple myeloma and acute myeloblastic leukemia: fact or myth. American Journal of Medicine 1984; 76: 891–899
   PubMed Web of Science ®Google Scholar
• Rosner F., Grunwald H. W. Multiple myeloma and Waldenström's macroglobulinemia terminating in acute leukemia. Review with emphasis on karyotypic and ultrastructural abnormalities. New York State Journal of Medicine 1980; 80: 558–570
   PubMedGoogle Scholar
• Kyle R. A., Pierre R. V., Bayrd E. D. Multiple myeloma and acute myelomonocytic leukemia. New England Journal of Medicine 1970; 283: 1121–1125
   PubMed Web of Science ®Google Scholar
• Bergsagel D. E., Bailey A. J., Langley G. R., MacDonald R. N., White D. F., Miller A. B. The chemotherapy on plasma-cell myeloma and the incidence of acute leukemia. New England Journal of Medicine 1979; 301: 713–748
   Web of Science ®Google Scholar
• Gertz M. A., Kyle R. A. Acute leukemia and cytogenetic abnormalities complicating melphalan treatment of primary systemic amyloidosis. Archives of Internal Medicine 1990; 150: 629–633
   PubMed Web of Science ®Google Scholar
• Schmetzer H. M., Mittermuller J., Duell T., Wilmanns W. Development of myeloma and secondary myelodysplastic syndrome from a common clone. Cancer Genetics and Cytogenetics 1998; 100: 31–35
   PubMed Web of Science ®Google Scholar
• Soenen V., Preudhomme C., Roumier C., Lai J. L., Lepelley P., Facon T., Pagniez D., Fenaux P. Myelodysplasia during the course of myeloma. Restriction of 17p deletion and p53 overexpression to myeloid cells. Leukemia 1998; 12: 238–241
   PubMed Web of Science ®Google Scholar